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Abstract 
Background & Aims: Celiac disease is an autoimmune disorder induced by 
ingestion of gluten that affects 1% of the population and is characterized by 
gastrointestinal symptoms, weight loss, and anemia. We evaluated the 
presence of neurologic deficits and investigated whether the presence of 
antibodies to TG6 increases the risk of neurologic defects in patients with a 
new diagnosis of celiac disease. 
 
Methods: We performed a prospective cohort study at a secondary-care 
gastroenterology center of 100 consecutive patients who received a new 
diagnosis of celiac disease based on gastroscopy and duodenal biopsy. We 
collected data on neurologic history, and patients were evaluated in a clinical 
examination along with magnetic resonance imaging (MRI) of the brain, MR 
spectroscopy of the cerebellum, and measurements of antibodies against 
TG6 in serum samples. The first 52 patients recruited underwent repeat MR 
spectroscopy at 1 year after a gluten-free diet (GFD). The primary aim was to 
establish if detection of antibodies against TG6 can be used to identify 
patients with celiac disease and neurologic dysfunction. 
 
Results: Gait instability was reported in 24% of the patients, persisting 
sensory symptoms in 12%, and frequent headaches in 42%. Gait ataxia was 
found in 29% of patients, nystagmus in 11%, and distal sensory loss in 10%. 
Sixty percent of patients had abnormal results from the MRI, 47% had 
abnormal results from MR spectroscopy of the cerebellum, and 25% had brain 
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white matter lesions beyond that expected for their age group. Antibodies 
against TG6 were detected in serum samples from 40% of patients±these 
patients had significant atrophy of subcortical brain regions compared to 
patients without TG6 autoantibodies. In patients with abnormal results from 
MR spectroscopy of the cerebellum, those on the GFD had improvements 
detected in the repeat MR spectroscopy 1 year later.  
 
 
Conclusions: In a prospective cohort study of patients with a new diagnosis 
of celiac disease at a gastroenterology clinic, neurological deficits were 
common and 40% had circulating antibodies against TG6. We observed a 
significant reduction in volume of specific brain regions in patients with TG6 
autoantibodies, providing evidence for a link between autoimmunity to TG6 
and brain atrophy in patients with celiac disease. There is a need for early 
diagnosis, increased awareness of the neurological manifestations amongst 
clinicians and reinforcement of adherence to a strict GFD by patients in order 
to avoid permanent neurological disability. 
 
 
 
Keywords: wheat, headaches, ataxia, peripheral neuropathy, brain atrophy 
 
 
 
What You Need to Know 
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Background: We evaluated the presence of neurologic deficits and 
investigated whether the presence of antibodies to TG6 increases the risk of 
neurologic defects in patients with a new diagnosis of celiac disease 
presenting to gastroenterologists. 
 
Findings: In a prospective cohort study of patients with a new diagnosis of 
celiac disease at a gastroenterology clinic, neurological deficits were common 
and 40% had circulating antibodies against TG6. We observed a significant 
reduction in volume of specific brain regions in patients with TG6 
autoantibodies. MR spectroscopy of the cerebellum improved after 1 year on 
a gluten-free diet. 
 
Implications for Patient Care: Our findings further emphasize the need for 
early diagnosis of celiac disease and strict adherence to a gluten-free diet in 
order to prevent permanent neurological disability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 6 
 
Celiac Disease (CD) is an autoimmune disease triggered by the ingestion of 
gluten. It affects 1% of the population.1 CD belongs to the spectrum of gluten-
related disorders that encompass diverse manifestations including Dermatitis 
Herpetiformis (DH), and neurologic dysfunction, the commonest of which is 
gluten ataxia (GA).2  
It remains unclear as to why in some patients the initial presentation is with 
gastrointestinal symptoms whilst in others it is primarily or exclusively with an 
itchy vesicular skin rash (DH) or with neurologic manifestations.3,4  
One possible explanation may lie in the primary immunological response 
targeting different potential auto-antigens (transglutaminases) and thus driving 
the respective primary clinical manifestation. This would be in keeping with 
the discovery of TG2 being the autoantigen in CD, TG3 the autoantigen in DH 
and TG6 the autoantigen in neurologic manifestations.5,6,7,8 The degree of 
overlap between CD and extraintestinal manifestations remains unknown, as 
does the potential for future development of such manifestations with ongoing 
exposure to gluten.  
It is assumed that neurologic symptoms and dysfunction in patients with newly 
diagnosed CD presenting to gastroenterologists are rare. To our knowledge, 
no study has utilized both detailed neurologic examination and brain imaging 
with MR spectroscopy to prospectively evaluate large numbers of such 
patients at the time of diagnosis.  
The primary aim of this study was therefore to establish if TG6 autoimmunity 
in the context of newly diagnosed CD patients is a marker of current 
neurological dysfunction. Secondly to clarify the true prevalence of neurologic 
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involvement as identified by detailed brain imaging and neurologic clinical 
evaluation at the time of diagnosis of CD, in patients presenting to 
gastroenterology clinics. Thirdly to prospectively study any changes on 
neuroimaging 12 months after the diagnosis of CD and the introduction of 
gluten-free diet (GFD).  
 
Methods  
Patient selection and clinical assessments 
This was a 3-year prospective study based at the Department of 
Gastroenterology, Academic Department of Neurosciences and Academic 
Department of Neuroradiology, Sheffield Teaching Hospitals NHS Trust, 
Sheffield, UK. The study was approved by the South Yorkshire Research 
Ethics Committee and informed consent was obtained from all participants. 
Patients were referred by their General Practitioners for investigation to a 
gastroenterology clinic run by one of the authors (DSS). All patients were from 
the catchment area of the Sheffield Teaching Hospitals NHS Trust. 
Consecutive patients with newly diagnosed CD were recruited during their 
gastroenterology appointment immediately after the biopsy results confirming 
CD were available. A history of previous neurologic diagnosis was an 
exclusion criterion, although none of the patients that agreed to participate 
had a prior history of neurologic consultation or diagnosis.  
 
Neurologic history and clinical examination 
All patients were clinically assessed by Consultant Neurologists. The 
Neurologists were blinded to the neuro-radiological findings and to the 
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serological results for TG6 autoantibodies. Patients were specifically asked if 
they had any balance problems (gait instability, tendency to fall, clumsiness), 
persisting sensory symptoms (tingling, numbness, peripheral pain in feet and 
hands) or frequent (weekly) headaches. If there was any clinical evidence of a 
peripheral neuropathy on clinical examination (distal sensory disturbance 
and/or areflexia) patients underwent neurophysiological assessments done by 
2 of the authors to verify the presence of neuropathy. The neurologic 
examination included detailed assessment of gait, including ability to tandem 
walk and stand on each leg in turn.  
 
Brain imaging  
Patients underwent MR imaging of the brain, including volumetric T1 weighted 
and volumetric FLAIR, and MR spectroscopy of the cerebellum (vermis and 
hemisphere). The methodology has been described previously.9 Any white 
matter disease on MRI was analyzed by 2 of the authors, neuroradiologists 
ZLWKRYHU\HDUV¶H[SHULHQFHDWVSHFLDOLVWQHXURUDGLRORJ\FRQVXOWDQWOHYHO
Both neuroradiologists were blinded to the TG6 serological status at the time 
of reporting. Scans were graded using the Fazekas scoring system and the 
number of white matter hyperintensities recorded from the volumetric FLAIR 
images with discrepancies resolved by consensus.10 Imaging data from 525 
healthy volunteers was used to correct for age related changes in 
morphometric assessments.  
Volumetry of key grey matter (GM) brain regions was based on processing of 
T1 images to generate normalized brain volume (NBV) data sets. Significant 
findings were further interrogated by age-controlled volumetry of sub-regions, 
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DQG³YHUWH[´VKDSHDQDO\VLVYLD³),567´where appropriate. Detailed 
methodology for image processing used is provided in the supplementary 
material. 
 
Serology 
Serological testing for TG2 IgA, antigliadin IgG and IgA (Aesku), endomysium 
antibodies and HLA typing was undertaken in all patients prior to the biopsy. 
None of the CD patients had IgA deficiency. All sera collected at baseline 
were tested for circulating anti-TG6 antibodies as part of the study, using 
previously described methodology.7,8 
 
Gluten-free diet follow-up  
The first 52 patients recruited were re-assessed after 1 year on GFD, 
including repeat brain imaging, telephone interview and serological status. 
Due to limited funding it was not possible to re-assess the entire cohort. 
 
Statistical analysis 
A database was developed using the Statistical Package for Social Science 
(version 23.0 for Mac; SPSS). Analyses sought to investigate differences in 
key MR variables relative to TG6 status, characterize the significance of 
different measures at presentation and examine the progression in relation to 
MR variables in the 1-year follow-up group. Frequencies and descriptive 
statistics were examined for each variable. Comparisons between groups 
were made XVLQJWKH6WXGHQW¶VW-test for the normally distributed continuous 
variables and the Mann-:KLWQH\¶V8 test for the non-normally distributed 
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continuous variables. Categorical variables were compared using the chi 
square test. Level of significance was set at the 95% confidence level. 
Statistical models employed to test significance of observed changes on 
imaging data are given in the Supplemental Materials section. 
 
Results  
A total of 100 consecutive newly diagnosed CD patients (60F and 40M) were 
recruited over 18 months. Reasons for referral included: one or more 
gastrointestinal symptoms (abdominal bloating, abdominal pain, weight loss, 
diarrhea, pale stools) in 54% of patients, anaemia in 16%, family screening in 
14%, persistent fatigue in 6%, irritable bowel syndrome diagnosed in primary 
care in 5%, osteoporosis in 4%, presence of other autoimmune diseases in 
4% and abnormal liver function tests in 3%. The mean age at the time of 
diagnosis of CD was 43±15 years (range 19 to 77). In line with a CD 
diagnosis, 97% of patients had circulating IgA TG2 autoantibodies, 90% had 
endomysium antibodies and 82% had circulating antibodies to gliadins (88% 
IgG, 75% IgA and 63% both).  All patients carried a CD susceptibility class II 
MHC, either HLA DQ2 (96%) or HLA DQ8 (4%). 
 
Clinical evaluation 
Detailed neurologic history revealed complaints of gait instability in 24% of 
patients, persisting sensory symptoms in 12%, and 42% with frequent 
(weekly) headaches, whereby 21% had more than one of these 3 neurological 
symptoms. On clinical examination, gait instability was found in 29% of 
patients. Sustained gaze-evoked horizontal nystagmus was observed in 11% 
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(all apart from 1 of these 11 patients also had gait instability), and distal 
sensory loss and/or areflexia suggestive of peripheral neuropathy in 10. A 
neurophysiological assessment indicated 1/10 with evidence of large fiber 
neuropathy and another with small fiber neuropathy. In total 67/100 patients 
had symptoms and/or signs of neurological dysfunction (Table 1). Excluding 
headache, which as a sole neurological symptom was present in 17% of 
patients, 50% of patients had symptoms and/or signs of neurological 
dysfunction. We did not identify any other contributory factors (e.g. vitamin 
deficiencies, presence of Diabetes Mellitus) that could potentially explain the 
above findings amongst those patients with neurologic deficits. 
 
Brain imaging 
MRI and MR spectroscopy was performed in 96 patients. Four patients did not 
have imaging, 2 due to claustrophobia, 1 was pregnant and one had a recent 
coronary stent insertion. In one patient the spectroscopy was unsuccessful. 
MR spectroscopy of the cerebellum was abnormal in 45/95 (47%) patients, in 
36 WKHDEQRUPDOLW\ZDVLQWKHYHUPLV1$$&UUDWLRLQ25 in the 
KHPLVSKHUH1$$&UUDWLRDQGLQ16 in both. The prevalence of 
abnormal MR spectroscopy was not significantly different in patients with 
clinically overt balance problems and those without (53.1% vs 42.2%; 
p=0.311). The number of patients with white matter lesions over and above 
what is expected from age was 24/96 (25%). This compared to 18/525 (3%) in 
healthy volunteers (p<0.001). There was no difference in the vascular risk 
factors or age between the group of patients with white matter changes and 
those without.  
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Stratification for TG6 autoantibodies 
Serologic testing for TG6 antibodies was done in 98 patients and were 
present in 39 (40%) patients (TG6 IgA : 28, TG6 IgG: 22, and both:11). This 
compared to 4% in the healthy population.8  
Combined MR imaging and TG6 serology was available in 95 participants of 
which 37 (40%) had circulating autoantibodies to TG6. Patients with TG6 
antibodies (TG6+) were significantly older than those without (TG6-): 
46.7±14.8 vs 40.3±14.8 (t-test, p=0.043). Abnormal imaging alone was not 
significantly linked to the presence of TG6 antibodies (26/38 [68.4%] in TG6+ 
vs 29/57 [50.9%] in TG6-, p=0.09).  However, 28/38 (73.7%) of TG6+ patients 
had abnormal MRS of the cerebellum and/or balance problems compared to 
26/57 (45.6%) of TG6- patients (chi square, p=0.007). Table 2 summarizes 
these findings. 
To investigate more specific imaging changes between the 2 groups we 
carried out a normalized brain volume (NBV) analysis for key regions. This 
revealed TG6+ patients to have significantly reduced cerebellar gray matter 
(GM) (NBVTG6+ / NBVTG6- = 7.554±0.808 / 7.869±0.718; independent t-test 
p=0.050), and subcortical GM (NBVTG6+ / NBVTG6- = 3.403±0.193 / 
3.503±0.192; p=0.016), but not cortical GM (NBVTG6+ / NBVTG6- = 
27.286±1.823 / 27.793±1.632; p=0.168) (Fig. 1). Further analysis controlling 
for age and including sub-regions was undertaken. This showed that, for the 
TG6+ group, NBV remained significantly reduced in the primary subcortical 
GM region, and was significantly reduced in the thalamus, but not in any other 
comparison (Table 3). There was a trend for abnormal atrophy in the TG6+ 
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group in three further cerebellar regions of interest (VIIb, VIIIa and Crus II, 
p<0.07). ),567³YHUWH[´DQDO\VLVZDVXVHGWR investigate the significant 
finding in the thalamus. Models that did not control for age were first used to 
visualise the overall spatial pattern of atrophy between the two groups (Fig. 
2a), showing a broad pattern of GM loss, with relative sparing of the anterior 
and pulvinar nuclei. With age correction applied (Fig. 2b), a significant locus of 
atrophy around the lateral / ventral posterior nuclei became evident. 
 
Follow-up after 1 year of GFD 
At one year, during telephone consultation with the first 52 patients recruited 
20/24 (83.3%) indicated that their headaches had improved (in 15) or 
completely resolved (in 5) following the introduction of GFD. 
All 52 patients underwent repeat brain imaging at one year (11.6 ± 1 month). 
Of the 23/52 patients who had abnormal NAA/Cr baseline vermian 
spectroscopy values, 12 (52.2%) improved to within the normal range. In 15 
patients (29%) there was an increase in the number of white matter lesions on 
the second scan. All apart from one of these patients already had white matter 
abnormalities at baseline. At the time of their second scan, 20 (47%) out of 43 
patients that had repeat serological testing still had positive serology (all had 
reduced levels compared to baseline; anti-TG6 antibody analysis was not 
performed at one year), suggesting inadequate compliance with GFD. We 
found no correlation between increased white matter lesions or change in MR 
spectroscopy and serological status at one year. The numbers however were 
very small.  
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Discussion  
To our knowledge this is the largest prospective study to perform detailed 
neurologic evaluation in patients with newly diagnosed CD presenting to 
gastroenterologists, using both clinical assessments and brain imaging 
including MR spectroscopy. The study suggests that 67% of patients with CD 
already have neurological symptoms and/or signs of neurological dysfunction 
at the time of diagnosis of CD: gait instability in 24% of patients, persisting 
sensory symptoms in 12%, and 42% with frequent headaches. Particularly 
notable was the presence of gait ataxia in 29% of CD patients.  
In addition 46% of patients had abnormal MR spectroscopy of the cerebellum 
and 25% had excessive white matter lesions over and above what is expected 
from age (3% in healthy population). Such neurological involvement often fails 
to be identified as it is unreported by patients and not questioned by 
gastroenterologists. As patients were from the local catchment area and 
referred by their local General Practitioners we believe that these findings are 
representative of adult patients with CD presenting to gastroenterologists.  
TG6 autoantibodies have been proposed as an early marker for neurological 
involvement in gluten-related diseases.8 In addition to TG6 autoimmunity, 
mutations of the TGM6 gene have been linked to ataxia.11,12  Our data provide 
further support for the utility of this marker in newly-diagnosed CD patients as 
a surrogate for brain involvement, as TG6 antibody positive patients displayed 
significant atrophy of subcortical brain regions, particularly the thalamus. TG6 
is expressed in a subset of neurons in the cerebellar cortex (Purkinje cells) 
and cerebellar nuclei but also in the thalamus.13,14 The thalamus is involved in 
motor control in terms of acting as a relay centre between the cerebellum and 
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the motor cortex.15 The observed significant thalamic atrophy and tendency 
towards cerebellar atrophy are therefore in line with loss or impairment of 
TG6+ neurons, potentially affecting GABA-ergic inhibitory pathways. This is in 
keeping with recent publications demonstrating brain hyper-excitability in 
patients with CD.16 
We have previously demonstrated that the prevalence of circulating TG6 
antibodies in CD patients presenting with ataxia is much higher than CD 
patients presenting to gastroenterologists (73% vs 40%), whereas the 
prevalence of TG6 antibodies in paediatric CD patients presenting to 
gastroenterologists was found to be 25%.17 The TG6 antibody prevalence in 
these 3 groups is analogous to what is observed in patients with DH where 
circulating TG3 antibodies (DH-specific epidermal autoantibodies) are found 
in up to 71% of patients with DH but in only 50% and 11% of adult and 
pediatric CD patients, respectively.18 It is noteworthy that in patients with DH, 
not all patients have circulating TG3 antibodies, yet 100% have IgA-TG3 
deposits in the papillary dermis, the site of the primary manifestation.19 
Therefore, while the presence of these antibodies (TG2, TG3 and TG6) in the 
serum is diagnostically helpful, their absence in the serum does not preclude 
a localized response at the level of the target tissue (gut, skin and brain). This 
observation may explain why some of the patients from this study with 
neurological symptoms and signs and/or abnormal imaging were negative for 
serum TG6 antibodies. Such patients may still be positive for TG6-specific 
plasma cells, may have TG6 antibodies in the cerebrospinal fluid and also 
have deposition of TG6 antibodies in brain tissue which can only be assessed 
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retrospectively, post-mortem. Indeed, the presence of such TG6 antibody 
deposits was demonstrated in the brain of gluten ataxia patients.7  
Data on the serological prevalence of TG6 in different gluten sensitivity-
related populations are sparse and have been performed by mainly using 
customized in-house TG6 antibody assays. One such study found the 
prevalence to be just 10% amongst a cohort of a mixture of neurology patients 
with CD or AGA positivity without enteropathy.20 Until such time as the 
widespread availability of a reliable and readily available standardized 
commercial TG6 assay in everyday clinical practice becomes a reality, it is 
difficult to draw any major conclusions on the differences in prevalence 
between published studies.   
 
The prevalence of peripheral neuropathy in the current cohort was low at 2%. 
Another study demonstrated evidence of peripheral neuropathy in 23% of 
patients with established CD.21 A population based epidemiological study on 
28,232 patients with CD showed a 2.5-fold increased risk for peripheral 
neuropathy.22  The low prevalence of peripheral neuropathy in our cohort 
suggests that gluten neuropathy may be a late manifestation of CD (the mean 
age at diagnosis of neuropathy in the cross-sectional study above was 51 
compared to 43.8 in the cohort studied here). This is consistent with our 
observation that for patients with CD presenting with neuropathy the average 
age at diagnosis of CD was 67. 
 
Twenty five percent of patients had significantly increased number of white 
matter abnormalities on MR imaging corrected for age, when compared to 
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healthy controls. Headaches, which subside with adherence to a GFD, and 
white matter abnormalities on MRI in CD patients have been previously 
reported using the term gluten encephalopathy.23 The largest population study 
on CD patients showed a significantly increased risk of headache-related 
visits.24   The majority of patients with CD and headache studied here 
indicated that their headache had improved or subsided (80%) after a year on 
a strict GFD. Similar percentage improvement (75%) has been reported in a 
recent systematic review of headache in CD.25  
The observation of high prevalence of white matter abnormalities in patients 
with CD has also been reported in a smaller study of 17 patients who were on 
GFD.26 The concern over the white matter abnormalities on MR imaging is 
their potential contribution to cognitive decline. A population study has 
suggested an increased risk of vascular dementia in patients with CD.27 The 
aetiology of the headache in CD patients remains unclear but an interesting 
study demonstrated regional cerebral blood flow hypoperfusion in patients 
with CD not on GFD when compared to healthy controls and patients with CD 
on GFD.28  
There are also some limitations to our study. We did not include a healthy 
control population alongside the CD group as the primary aim was to 
investigate differences between CD patients positive or negative for TG6 
antibodies. It is therefore difficult to know how the prevalence of the clinical 
findings would compare to a healthy population examined in the same setting. 
However, the literature provides some guidance. A smaller cross-sectional 
study in patients with established CD (mean age 51 years), demonstrated 
stance and gait instability in 33% of patients, a figure similar to what we 
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found.29 A study assessing the prevalence of gait instability in 115 healthy 
volunteers (same mean age as our group) found that none had gait 
instability.30 Another study of untreated patients with CD showed the presence 
of neurological symptoms to be 15% compared to 0% in healthy controls.31  
Only half of the cohort of patients neurologically assessed at baseline 
underwent repeat imaging at 1 year. This was due to limited funding. However 
the beneficial effect of GFD in patients with GA, using MR spectroscopy as 
the outcome measure has already been reported in a much larger cohort of 
117 patients.9  
In conclusion, neurological dysfunction in patients with newly diagnosed CD 
presenting to the gastroenterologist is common but overlooked. TG6 
antibodies are prevalent amongst patients with newly diagnosed CD and are 
associated with regional brain atrophy. Given the early presence of 
neurological dysfunction including brain atrophy there is a need for early 
diagnosis, increased awareness of the neurological manifestations amongst 
clinicians and reinforcement of adherence to a strict GFD by patients in order 
to avoid permanent neurological disability. 
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Figure legends 
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Fig. 1     Brain atrophy in patients with TG6 autoantibodies.  
Box plots visualizing normalized brain volumes (NBVs) for cerebral cortical 
(top left), subcortical (top right), and cerebellar cortical (bottom) grey matter 
for TG6 antibody positive or negative CD patients (asterisk: p<0.05, 
independent t-test).  
 
Fig. 2     Visualisation of TG6 antibody-related atrophy in the thalamus. 
TFCE-FRUUHFWHGRXWSXWIURP),567³YHUWH[´DQDO\VLVRIWKHWKDODPXV before 
(A) and after (B) correction for age-related changes.  
A. Red locations highlight areas which have significantly (pDWURSKLHGLQ
the TG6+ group compared to the TG6- group.  
B. Red areas as above while blue areas identify locations where (pIRU
reference (top & middle); differences only reached significance in the left 
thalamus (middle). However, when reducing the threshold for red areas to 
pLQWKHULJKWWKDODPXVDYHU\VLPLODUSDWWHUQWRWKHOHIWLVUHYHDOHG 
(bottom).  
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Table 1: Neurological evaluation of newly diagnosed CD patients 
 
Number of patients with CD 
presenting to gastroenterologists 
recruited 
100 
Mean age at diagnosis 43±15 years (range 19-77) 
Total number with symptoms and/or 
signs of neurological dysfunction 
67% 
Symptoms gait instability 
loss of balance 
24% 
persisting 
sensory 
disturbance 
12% 
frequent 
headaches 
42% 
Signs gait ataxia 29% 
nystagmus 11% 
sensory loss 
and/or areflexia 
10% 
Excluding headache, total number 
with symptoms and signs of 
neurological dysfunction 
50% 
Abnormal MR spectroscopy of the 
cerebellum 
45/95 (47%) 
White matter abnormalities on MR 
brain imaging (excessive for age) 
25% (3% in healthy controls) 
Number of patients undergoing MR 
imaging at one year 
52/100  
Abnormal cerebellar spectroscopy 
at baseline 
23/52 (44.2%) 
Normalization of MR spectroscopy 
at one year 
12/23 (52.2%) 
Number TG6 positive CD patients 40% 
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Table 2: Differences between patients with CD positive for TG6 antibodies 
compared to those negative for TG6 antibodies. * significant 
 
 TG6 +ve TG6-ve p value 
age 46.7 40.3 0.043* 
abnormal brain 
imaging 
68.4% 50.9% 0.09 
abnormal MR 
spectroscopy of 
the cerebellum 
and gait ataxia 
73.7% 45.6% 0.007* 
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Table 3: Volumetric analysis of individual brain regions following stratification 
for TG6 autoantibody positivity revealed significant differences in age-
controlled ANOVAs. 
 
         37 patients     58 patients 
 ROI 
TG6+ 
 Mean(SD) 
NBV 
TG6- 
Mean(SD) 
NBV 
TG6    
positivity 
p value 
Age 
correct.  
p value 
Freesurfer 
Volumes 
Subcortical 
GM 3.403(0.193) 3.503(0.192) .045 .050 
Thalamus 0.928(0.066) 0.973(0.085) .035 .002 
Caudate 0.397(0.041) 0.400(0.048) .406 .015 
Putamen 0.581(0.072) 0.604(0.054) .221 .005 
Globus 
Pallidus 0.177(0.022) 0.179(0.016) .823 .025 
Hippocampus 0.519(0.051) 0.523(0.040) .750 .697 
Amygdala 0.175(0.022) 0.182(0.017) .096 .752 
SUIT 
Volumes 
Cerebellum 
GM 7.554(0.808) 7.869(0.718) .110 .097 
I-IV 0.449(0.053) 0.470(0.048) .121 .027 
V 0.588(0.061) 0.608(0.054) .154 .266 
VI 1.224(0.126) 1.266(0.114) .163 .218 
VIIb 0.619(0.063) 0.645(0.057) .065 .385 
VIIIa 0.589(0.061) 0.615(0.055) .055 .407 
VIIIb 0.478(0.052) 0.497(0.045) .118 .161 
IX 0.417(0.051) 0.432(0.043) .327 .004 
X 0.060(0.011) 0.064(0.010) .209 <.001 
Vermis 0.351(0.041) 0.364(0.037) .259 .024 
Crus I 1.625(0.180) 1.700(0.163) .103 .027 
Crus II 1.155(0.120) 1.207(0.110) .064 .222 
   
 
 
